• CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer.
• In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit.
• In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation.
• A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade.
• Industry reports estimate that the global brain tumor therapeutics market will reach $2.74 billion in 2023 and $3.4 billion by 2025, up from $2.25 billion in 2019.

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (“API”) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://ibn.fm/QOqjB).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Legal marijuana market set to top more than $90 billion by 2027
• Pac Roots places top priority on developing, delivering finest cannabis genetics
• Optimized farming systems employed in most fertile areas means maximum opportunity for harvest

After experiencing a few roadblocks over the last year, the cannabis sector looks to be picking up speed. In fact, a recent Data Bridge Market Research study reports that the global legal marijuana market should top more than $90 billion by 2027 (https://ibn.fm/UE8Tj). Pac Roots Cannabis (CSE: PACR), a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, has taken strategic steps to be in a strong position as the market heads upward.

For starters, the company is leveraging its expertise in cultivating quality flowers. “Pac Roots is dedicated to delivering the finest cannabis genetics to its consumers, preserving the excellence of its carefully cultivated elite strains while also working to introduce superior new strains,” a recent article spotlighting the company reported (https://ibn.fm/RQHKp). “While some companies may strive to be the largest cannabis grower, Pac Roots believes that the quality of the product is paramount.”

PACR is able to do maintain this strict commitment to quality through a strategic licensing agreement with Phenome One Corp, which gives Pac Roots complete access to one of Canada’s largest live, genetic cannabis libraries (https://ibn.fm/XAG9K). This unparalleled resource allows Pac Roots and Phenome One to develop elite strains with multiple beneficial characteristics. PACR’s extensive catalog features more than 350 tested cultivars, with some 50 qualifying for the super-elite category.

In addition, Pac Roots has carefully chosen superior growing sites, including Rock Creek Farms, located in the South Okanagan Valley in British Columbia. The area, known as the Golden Mile, has even been called the Napa Valley of the North. The 100-acre, premium hemp farm is a joint venture that Pac Roots started with Rock Creek Farms earlier this year after receiving a hemp cultivation license from Health Canada.

Pac Roots has also announced completion of a share purchase agreement of 250 acres of pristine property in the Fraser Valley Regional District of British Columbia. In the agreement, Pac Roots has acquired all of the issued and outstanding shares of 1088070 BC. Ltd., which owns land in one of the most productive and intensively farmed areas in Canada.

Pac Roots works closely with its partners to optimize cultivation through unique proprietary methods, including the use of custom-formulated nutrients made from raw sales; systematic planting of young, hardy cultivars; row compaction and mowing for weed control; and a complex irrigation system that delivers nutrients and spring water directly to each plant.

Pac Roots began operations in 2012 with initial activities directed toward exploration and development of mineral properties in Canada. The company’s mission has evolved through time, and today, PacRoots is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top-quality products. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company’s passion. Genetic variation and stability are the foundation that drives the decision-making for Pac Roots Cannabis Corp.’s business.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027
• Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade
• The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States.
• 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020

Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most significant driver of disease – inflammation. Part of the body’s natural defense system by removing foreign stimuli from the body to begin the healing process, inflammation plays a significant role in a wide range of diseases and ailments, including asthma, arthritis, psoriasis, COVID-19 and more.

Inflammation within the body presents itself in two forms – acute and chronic. The World Health Organization (“WHO”) ranks chronic diseases (like a chronic inflammatory disease) as the most significant risk to human health. The conditions associated with chronic inflammation are anticipated to increase persistently over the next 30 years within the United States.

In 2014, the Rand Corporation estimated that 60% of Americans had at least one chronic condition, 42% had more than one, and 12% of adults had five or more chronic conditions. In 2000, 125 million Americans lived with chronic diseases, and 61 million had more than one (https://ibn.fm/jE8Tw).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

The company’s fibrosis and anti-TNF clinical trials (phase 2b/3) are conducted at the Kennedy Institute within Oxford University and led by Professor Jagdeep Nanchahal and Professor Sir Marc Feldmann. The first results of these trials, addressing four critical areas of inflammation – Dupuytren’s disease, frozen shoulder, post-operative cognitive deficit, and liver fibrosis and nonalcoholic steatohepatitis – are expected in 2021.

180 Life Sciences is also running two preclinical stage trials regarding chronic inflammatory pain (at the Hebrew University in Israel and led by Professor Raphael Mechoulam) and the a7nAChR nicotine receptor and its role in the body’s method of controlling inflammation (at Stanford University and led by Professor Lawrence Steinman and Dr. Jonathan Rothbard).

The company’s work addressing inflammation makes it an attractive investment, as its potential for growth is significant given the size and expansion rate of the anti-inflammatory therapeutics market. According to Allied Market Research, the anti-inflammatory drug therapy market is expected to grow to approximately $106.1 billion annually in 2020 (https://ibn.fm/iC9AZ). From 2015 to 2020, the registered CAGR would be 5.9%. According to Fortune Business Insights, the market is expected to continue growing and generating revenue of $191.42 billion through 2027 (https://ibn.fm/d9Zp4).

In addition, Professor Sir Marc Feldmann, who leads the Fibrosis & Anti-TNF trial, has already developed and marketed an anti-TNF drug (Remicade). He developed this very first anti TNF inhibitor with Dr. James Woody, who was Chief Scientific Officer at Centocor, and will serve as CEO of 180LS. Remicade was the primary driver in the $4.9 billion acquisition of Centocor by Johnson & Johnson in 1998.  Remicade was developed with the Today, Remicade remains one of the bestselling anti-TNF drugs for Johnson & Johnson. The global sales for anti-TNFs in 2016 were $36 billion.

180 Life Sciences Corp. is currently nearing the end of a merger with special purpose acquisition company KBL Merger Corp. IV (NASDAQ: KBLM), which should finalize in Q4 2020. Once the merger has been completed, 180 Life Sciences will be listed on the NASDAQ Capital Market under the ticker symbol ‘ATNF.’ At present, KBL Merger Corp. IV values 180 Life Sciences Corp. at an estimated $175 million, with the acquisition being carried out through share swapping.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180

• Streaming sites are among businesses that have seen an uptick in sales during worldwide pandemic
• Content key for companies in streaming space
• The Movie Studio moving forward in space, expanding content and keeping costs down

Not all businesses are struggling through the worldwide pandemic. A recent CompariTech article reported that streaming video is becoming a viable option for a growing number of viewers around the world, resulting in increasing numbers for companies involved in streaming content (https://ibn.fm/wSNni). The Movie Studio (MVES), a vertically integrated motion picture production and distribution company, is looking to become a major player in this star-studded industry, which now has national and international streaming services operating in almost every country.

“While many businesses have struggled due to stay-at-home orders, streaming sites are among the businesses that have seen an uptick in sales,” the article observed. “For example, Netflix added almost 16 million subscribers during the first three months of 2020. It attributed this high number to the fact that people are spending so much more time at home. Disney+ is another big winner, and an uptick in new subscribers pushed it past sister service Hulu in terms of user numbers.”

The article also noted the importance of content, with Netflix reportedly spending more than $17 billion on content in 2020; the company plans to spent $26 billion by 2028. And while content is key, a recent Nielsen Total Audience Report noted that cost, ease of use, and variety are also important streaming-service attributes (https://ibn.fm/t83gv).

Specifically, the report stated that 84% of users rank cost as an extremely or very important attribute when selecting a streaming service. This is closely followed by ease of use (81%), variety or availability of content (79%), streaming and playback quality (77%), and speed of menu selection and content loading (74%).

Aware of these key factors, the Movie Studio is strategically moving forward in the sector. The company is expanding its content by purchasing legacy film libraries — and then upgrading the acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the Internet. In addition, the company is currently in production of three original-content films: “Cause and Effect,” “The Last Warhead” and “Pegasus.”

With a priority on keeping costs down and creativity up, the Movie Studio is establishing a proprietary OTT VOD platform to distribute both its own and aggregated feature film projects, television programming and other media intellectual properties. In addition, the company is pioneering new media content-delivery systems with its digital business model of motion picture distribution as well as its plans to create a direct-server access platform of its content for worldwide distribution. In each effort, the Movie Studio is placing a high premium on accessibility, ease of use, quality of service and functionality.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• Sanwire Corp. is using technology to consolidate services in fragmented markets. The company is currently focused on advanced entertainment technologies.
• The acquisition of Intercept Music Inc. gave Sanwire solid footing in the music and entertainment industry, offering a unique suite of artist-focused services specifically created for recording artists.
• During the second quarter of 2020, Sanwire’s revenues increased by approximately 300% following its acquisition of Intercept Music Inc. Further growth is expected throughout the balance of 2020.
• On June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart.

Sanwire Corp. (OTC: SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

• Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
• Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
• The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

• Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
• Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
• Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (https://ibn.fm/G09cu). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (https://ibn.fm/eCcds).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (https://ibn.fm/BQX82). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

For more information, visit the company’s website at www.SanwireCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to SNWR are available in the company’s newsroom at https://ibn.fm/SNWR

• POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition
• Founder calls contract “major milestone,” validation of move into new facility
• POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization

Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies.

“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”

Soluble Biotech is fast becoming recognized for its ability to enhance the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.

“With our first contract on the books, and expanded capacity, the future is bright,” said DeLucas. “We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”

In addition to this POAI milestone, the company also announced that its Skyline Medical division has sold eight of its proprietary STREAMWAY systems to a large Virginia-based university hospital organization for use in a new surgical center (https://ibn.fm/JQ6AA); the hospital system previously purchased two STREAMWAY systems, which are currently in use.

The FDA-approved and CE-marked STREAMWAY Systems provide automated, direct-to-drain medical fluid disposal that is changing the way health-care facilities collect and dispose of potentially infectious waste fluid. The eight-system sale brings the total systems sold for Q3 2020 up to 13.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SGTM secures Hurricane Laura recovery work contract for ArborPro of Mississippi Inc.
• Initial relief efforts will divert trees from landfills to temporary holding sites
• SGTM transforms natural storm waste into organic environmentally beneficial products

As “stewards of the environment”, Sustainable Green Team (OTC: SGTM) takes its role in environmental remediation seriously by providing beneficial solutions for tree and storm waste disposal. In the wake of Hurricane Laura, SGTM rose to the occasion by securing a contract for ArborPro of Mississippi Inc. (APM), one of its strategic partners. The recovery work planned will kickstart SGTM’s process, diverting many destroyed trees from landfills to the company’s processing facilities that will transform them into environmentally beneficial organic products.

Considered to be the strongest hurricane to hit Louisiana since 1856, Laura ravaged the state with winds clocking in at over 150 miles per hour as it destroyed vegetation and shredded homes while taking at least 17 lives in the process (https://ibn.fm/LXAc5). Hurricanes of this magnitude inflict massive damage on trees by breaking branches or uprooting them completely, creating a burden for municipalities that often dispose of them in landfills.

SGTM provides synergistic solutions that clear devastated areas of natural waste while creating products that benefit the environment. Through its subsidiary National Storm Recovery, the company collects the trees and transforms them into organic products such as garden mulch and organic playground surfacing material certified by IPEMA, The International Play Equipment Manufacturers Association.

“Our teams are committed to the cleanup process and helping the wonderful people of Louisiana get back on their feet again,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/xsOVe). “Our database of subcontractors is growing daily as the clean-up efforts begin.”

Teams from both SGTM and APM will initially collaborate with subcontractors to remove trees blocking key infrastructure points such as right-of-ways. As part of the initial remediation efforts, the trees will then be transported to temporary debris management sites for storage prior to reaching their final destination at SGTM’s processing facilities.

“I’m proud to be a part of this disaster recovery clean up and with our relationship with National Storm Recovery,” said APM CEO Aaron Miller. “Our combined resources and decades of experience will speed the recovery process.”

SGTM’s solutions are founded in sustainability, based on vertically integrated operations that transform what would be landfill waste into organic, attractive, next-generation playground surface material and mulch products that are packaged and sold to landscapers, installers and garden centers. Through a combination of organic growth, strategic acquisitions and service diversification, the company is positioned for rapid growth as nationwide demand for environmentally sustainable solutions for natural waste continues to increase.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/JVHu6.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Pressing need for efficient drug procurement, delivery as costs rise
• Trxade platform speeds up delivery, cuts costs
• Such efficiencies crucial to keeping America’s independent pharmacies alive
• Around half of 24,000 independent pharmacies have already signed on

These days, critics of the U.S. health-care system may be tempering their censure. After all, the sector has proved its worth in the battle against the coronavirus pandemic. Yet some of the fault-finding had merit. The system is bloated and plagued by inefficiencies. Even doctors agree, as a recent report in the “Journal of the American Medical Association” (“JAMA”) indicates (https://ibn.fm/bL7C1). Digital technologies may help streamline processes and methodologies, making some areas, such as pharmaceutical distribution, more efficient and, importantly, more effective. With that in mind, the Trxade Group (NASDAQ: MEDS) has developed a pharmaceutical supply-chain trading platform that is already helping pharmacies cut costs and get faster delivery.

No other country spends more on health care than the United States. National expenditure in the sector accounts for around 18% of gross domestic product (“GDP”). Unfortunately, recent studies have shown a lot of that money just goes down the drain. That conclusion, published in JAMA, details that “approximately 30% of health care spending may be considered waste.”

A major portion of that — $230.7 billion to $240.5 billion — can be attributed to “pricing failure,” which includes “medication pricing, payer-based health services pricing, and laboratory-based and ambulatory pricing.” Of these, medication pricing is posing the biggest challenge, as new high-cost specialty drugs become more widely prescribed. But, say researchers, cost pressures in pharmaceuticals can be reduced by “increasing market competition… and reforming price transparency,” which is exactly what the Trxade pharmaceutical trading platform is designed to do (https://ibn.fm/I0H6D).

The web-based platform allows pharmacies to discover the best-available prices for prescription drugs, a feature that independent pharmacists find especially advantageous. It also helps pharmacies avoid negative reimbursement costs, which reduce already thin profit margins. The Trxade Group is hoping to show most, if not all, of the 24,000 independent pharmacies that its platform is a better deal than the conventional system, and the company appears well on the way to doing so. An estimated 11,400 pharmacies have already signed up.

These cost pressures are particularly trying for independent pharmacies that are competing with giant chains such as CVS, Walgreens, Rite Aid and Walmart. In the past, these smaller businesses have depended on pharmacy benefit managers (“PBMs”) to reduce the purchase costs of drugs. PBMs are third-party administrators of prescription drug programs that were supposed to contribute to lower prices by their consolidation of buying power.

However, it appears the cost savings procured have been mainly used by PBMs to build their own businesses. Some PBMs now have revenues that exceed those of the top pharmaceutical manufacturers. For example, Express Scripts reported revenue of $100 billion in 2017, about twice as much as Pfizer, which is the largest pharmaceutical company in the world. Incredible as it may seem, the distribution of pharmaceuticals is a much more lucrative business than the manufacture of pharmaceuticals. Indeed, distribution margins also exceed those earned by pharmacies at the retail level.

However, the online marketplace hosted by the Trxade Group offers pharmacies a real opportunity to reduce purchase costs. Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. By increasing competition and price transparency, the Trxade Exchange is giving today’s independent drugstores a new lease on life.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• KAVL recently announced the Bidi(TM) Vapor Premarket Tobacco Product Application submission to FDA, a premium recyclable vape pen
• Application includes 285,000 pages with science-backed evidence that Bidi(TM) Sticks are Appropriate for Protection of Public Health (“APPH”)
• KAVL and Bidi(TM) Vapor fully support proper regulation of safety manufacturing and marketing of vape products
• Bidi(TM) Sticks are produced in 11 flavors with 6% nicotine concentration

With a focus on growing and incubating innovative products into mature dominant brands, Kaival Brands Innovations Group (OTCQB: KAVL) recently entered into a partnership with Bidi (TM) Vapor, LLC for exclusive global distribution rights for the Bidi(TM) Stick – a new game-changing recyclable vape pen that offers users a premium multi-flavored vaping experience. Bidi(TM) Vapor recently announced that it has submitted its Premarket Tobacco Product Application (“PMTA”) to the U.S. Food and Drug Administration (“FDA”) for approval to continue its marketing efforts in the United States.

Vape pens, also known as electronic cigarettes, are devices used to supplement nicotine with vapor instead of smoke from combustible cigarettes. Accordingly, Bidi(TM) Vapor’s application provides over 285,000 pages of extensive science-based evidence demonstrating how Bidi(TM) Sticks are “Appropriate for the Protection of Public Health” (“APPH”).

“Bidi(TM) Stick is a premium-quality product that adult smokers have discovered can be a viable alternative to combustible tobacco, and we look forward to meeting the increasing market demand for the innovative product,” said Kaival Brands president and CEO Kaival Niraj Patel.

Using science as a foundational base, Bidi(TM) Vapor engineered its electronic nicotine-delivery system (“ENDS”) products using its own patented technology. With stringent quality control standards in place, the company vetted all supplementary raw chemicals and components purchased for the manufacturing process in a cGMP (current Good Manufacturing Practice) facility. Following strict in-vitro and in-vivo toxicity testing (including genotoxicity tests) at a GLP (Good Laboratory Practice)-approved lab, the product was then subjected to an HPHC (Harmful and Potentially Harmful Constituents) analysis of both the aerosol and e-liquid in ISO 17025 certified labs.

Also contained in the PMTA submission were three independent surveys and one combined consumer survey of people aged 21+ conducted by Bidi(TM) Vapor. The application also included specific information concerning the product’s 11 flavors in addition to details on its nicotine concentration that stands at 6% weight/volume.

“Both Kaival Brands and Bidi(TM) Vapor fully support proper regulation of the category so that all ENDS products meet the highest manufacturing, safety and marketing standards for adult smokers, with the ultimate goal of improving public health,” Patel continued. “We look forward to working with Kaival Brands as we work with the FDA to construct its regulatory policy based on science and facts.”

Kaival Brands is dedicated to developing innovative and viable options for adults currently using combustible tobacco products who are opting for a healthier and more satisfying experience. The company intends to set high standards and transform perceptions with the overall goal of exceeding customer expectations and increasing market share in the continuously growing vaping industry.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• GoldHaven to trade on OTCQB under ticker symbol ATUMF
• Move provides liquidity in trading of shares, creates opportunity for American investors to participate in Maricunga Gold Belt activity
• GoldHaven recently entered into agreements to acquire seven gold projects, plans aggressive drill program

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, has announced that it has been accepted for trading on the OTCQB (https://ibn.fm/fB9Z3). The OTCQB exchange is a United States stock market based in New York City and operated by OTC Markets Group. The shares will trade on OTCQB under the ticker symbol ATUMF.

“We are very pleased to begin trading on OTCQB and continue our outreach into the U.S,” said GoldHaven president and CEO David Smith. “Further, it will provide liquidity in the trading of its shares and create an opportunity for American investors to participate in the company’s investment in the Maricunga Gold Belt. We look forward to providing the market with frequent updates as we plan on the implementation of an aggressive drill program in the first quarter of the coming year.”

This news comes on the heels of the announcement by GoldHaven that it has recently entered into agreements to acquire seven promising gold projects in the highly productive Maricunga Gold Belt of Chile. Within the past 20 years, discoveries totaling in excess 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper have been made in this belt.

Thus far, GoldHaven has identified four of those seven properties as high-priority targets and anticipates beginning a drilling program by January 2021. The process of identifying and categorizing these projects was extensive. Careful field evaluations included mapping, geochemical sampling and satellite imagery.

Location is also a key component for GoldHaven’s Coya project, which is situated within close proximity to one of the richest and largest epithermal gold and silver districts in Chile. The La Coipa property, an active mining site owned and operated by Kinross, is also in close proximity, with reported production of more than 6.2 million ounces of gold to date.

The movement on these projects is particularly timely, given the recent meteoric rise of the price of gold. The current fragile state of the global economy, caused in part by the weakening U.S. dollar, has spurred the price of gold to reach $2,000 an ounce for the first time ever (https://ibn.fm/Zw67Q). Projections call for that number to go even higher, perhaps even reaching $3,000 per ounce (https://ibn.fm/uCdmd). That can only benefit companies such as GoldHaven, which are working to become strong players in the gold space.

GoldHaven is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 13 billion lbs. copper.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://ibn.fm/ATUMF